CorMedix (CRMD) PT Raised to $18 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $5.43 -4.74%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 17
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 17
Join SI Premium – FREE
Truist Securities analyst Joon Lee raised the price target on CorMedix (NASDAQ: CRMD) to $18.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- CorMedix reaffirms 2026 revenue guidance, reports $355M cash
- Lumentum (LITE) PT Lowered to $1,132 at Mizuho
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
